公开(公告)号：US11524992B2

公开(公告)日：2022-12-13

申请号：US16751788

申请日：2020-01-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Joseph Toth ,  Ginger C. Rakestraw ,  Irvith M. Carvajal ,  Stanley Richard Krystek, Jr. ,  Steven R. O'Neil ,  Guodong Chen ,  Richard Y. Huang ,  Bryan C. Barnhart ,  John Thomas Loffredo ,  Christina Terragni

IPC: C07K14/78 ,  A61K47/64 ,  G01N33/68 ,  A61K38/00 ,  A61K47/60

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

公开(公告)号：US20230174647A1

公开(公告)日：2023-06-08

申请号：US17845742

申请日：2022-06-21

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/563 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/563 ,  G01N33/577 ,  A61K2039/505

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

公开(公告)号：US10584160B2

公开(公告)日：2020-03-10

申请号：US15760449

申请日：2016-09-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dasa Lipovsek ,  Joseph Toth ,  Ginger C. Rakestraw ,  Irvith M. Carvajal ,  Stanley Richard Krystek, Jr. ,  Steven R. O'Neil ,  Guodong Chen ,  Richard Y. Huang ,  Bryan C. Barnhart ,  John Thomas Loffredo ,  Christina Terragni

IPC: C07K14/78 ,  A61K47/64 ,  G01N33/68 ,  A61K38/00

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

公开(公告)号：US20200079848A1

公开(公告)日：2020-03-12

申请号：US16506754

申请日：2019-07-09

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  G01N33/577 ,  G01N33/563 ,  A61P35/00

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.